Sacituzumab govitecan: all 103 studies that test it
Page 1 of 2. Open to participants first (54), then studies with results posted, then the rest; newest registration first within each.
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
- Sacituzumab Govitecan and Q901 in Advanced TNBCNot yet recruitingNCT07788222Phase 2
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingNCT07504588Phase 2
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07492914Phase 2
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLCNot yet recruitingNCT07438600Phase 2
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
- Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingNCT07368543Phase 2
- Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast CancerNot yet recruitingNCT07367178Phase 2
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBCEnrolling by invitationNCT07359404Phase 2
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingNCT07299409Phase 2
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07151586Phase 2
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 2
- Trop-2 Targeted PET Probes in Advanced TNBCRecruitingNCT07046455Not applicable
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingNCT07040644Phase 2
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingNCT07011654Phase 1/2
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2
- Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingNCT06923826Phase 2
- A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid TumorsRecruitingNCT06827613Phase 1/2
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Phase 3
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingNCT06665178Phase 2
- Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT06616987Phase 2
- Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingNCT06528483Phase 2
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3
- A Study of Sacituzumab Govitecan in People With MesotheliomaRecruitingNCT06477419Phase 2
- Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast CancerRecruitingNCT06462092Phase 1/2
- Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain MetastasesNot yet recruitingNCT06462079Phase 2
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
- Sacituzumab Govitecan and Bevacizumab for NSCLC Brain MetastasesRecruitingNCT06401824Phase 2
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06329869Phase 2
- HCQ+ADC vs ADC in the Treatment of Advanced Breast CancerRecruitingNCT06328387Phase 1/2
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingNCT06263543Phase 2
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingNCT06248515Phase 2
- Sacituzumab Govitecan in Metastatic Colorectal CancerRecruitingNCT06243393Phase 2/3
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingNCT06238921Phase 1/2
- HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab GovitecanRecruitingNCT06236269Phase 2
- Sacituzumab govitEcan in THYroid CancersRecruitingNCT06235216Phase 2
- Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersRecruitingNCT05884320Phase 2
- A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingNCT05838521Phase 2
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingNCT05833867Phase 1
- Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyRecruitingNCT05770531Phase 2
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingNCT05633654Phase 3
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
- Scalp Cooling in MBCRecruitingNCT04986579Phase 2
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentRecruitingNCT04617522Phase 1
- Sacituzumab Govitecan in Recurrent GlioblastomaRecruitingNCT04559230Phase 2
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedNCT06865677Phase 2Results posted
- Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerTerminatedNCT05581589Phase 2Results posted
- Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2Results posted
- Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05089734Phase 3Results posted
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedNCT04927884Phase 1/2Results posted
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadCompletedNCT04527991Phase 3Results posted
- Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziyCompletedNCT04319198Phase 4Results posted
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsActive, not recruitingNCT03964727Phase 2Results posted
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedNCT03901339Phase 3Results posted
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
- Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed TherapyActive, not recruitingNCT03725761Phase 2Results posted
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
- Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results posted
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerWithdrawnNCT07328490Phase 1/2
- Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnNCT07134556Phase 2
- Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerActive, not recruitingNCT06612203Phase 1/2
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)Active, not recruitingNCT06486441Phase 3
- Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaActive, not recruitingNCT06178588Phase 2
- PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingNCT06133517Phase 2
- Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric AdenocarcinomaCompletedNCT06123468Phase 1/2
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Active, not recruitingNCT06100874Phase 2
- Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2
- A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsActive, not recruitingNCT06028932Phase 2
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyActive, not recruitingNCT05840211Phase 3
- A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Active, not recruitingNCT05675579Phase 2
- Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingNCT05633667Phase 2
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Phase 3
- Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerActive, not recruitingNCT05552001Phase 3
- Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDCompletedNCT05520723Phase 2
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Phase 3
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382286Phase 3
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder CancerCompletedNCT05226117Phase 2
- Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1
- Study of Sacituzumab Govitecan in Patients With Solid TumorActive, not recruitingNCT05119907Phase 2
- Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsActive, not recruitingNCT05101096Phase 1/2
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsCompletedNCT04826341Phase 1/2
- Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesActive, not recruitingNCT04647916Phase 2
- Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingNCT04639986Phase 3
- Sacituzumab Govitecan in Primary HER2-negative Breast CancerActive, not recruitingNCT04595565Phase 3
- Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsActive, not recruitingNCT04454437Phase 2
- A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaActive, not recruitingNCT04251416Phase 2
- Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Active, not recruitingNCT04039230Phase 1/2
- Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0CompletedNCT03995706Early Phase 1